E
Ellen Freed
Researcher at Harvard University
Publications - 5
Citations - 1272
Ellen Freed is an academic researcher from Harvard University. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 5, co-authored 5 publications receiving 1168 citations.
Papers
More filters
Journal ArticleDOI
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Ron Firestein,Adam J. Bass,So Young Kim,Ian F. Dunn,Serena J. Silver,Isil Guney,Isil Guney,Ellen Freed,Azra H. Ligon,Natalie Vena,Shuji Ogino,Milan G. Chheda,Milan G. Chheda,Pablo Tamayo,Stephen P. Finn,Yashaswi Shrestha,Yashaswi Shrestha,Jesse S. Boehm,Supriya Rani Jain,Emeric Bojarski,Craig H. Mermel,Craig H. Mermel,Jordi Barretina,Jordi Barretina,Jennifer Ang Chan,José Baselga,Josep Tabernero,David E. Root,Charles S. Fuchs,Massimo Loda,Ramesh A. Shivdasani,Matthew Meyerson,William C. Hahn +32 more
TL;DR: It is shown that the suppression of CDK8 expression inhibits proliferation in colon cancer cells characterized by high levels ofCDK8 and β-catenin hyperactivity, suggesting that therapeutic interventions targeting CDK 8 may confer a clinical benefit in β-Catenin-driven malignancies.
Journal ArticleDOI
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
John Souglakos,Juliet Philips,Rui Wang,S Marwah,M Silver,Maria Tzardi,Jonathan S. Silver,Shuji Ogino,Shuji Ogino,Susanne M. Hooshmand,Eunice L. Kwak,Ellen Freed,Jeffrey A. Meyerhardt,Z. Saridaki,V. Georgoulias,Dianne M. Finkelstein,Charles S. Fuchs,Matthew H. Kulke,Ramesh A. Shivdasani +18 more
TL;DR: These results underscore the potential of mutational profiling to identify CRCs with different natural histories or treatment responses and the adverse significance of BRAF mutation should inform patient selection and stratification in clinical trials.
Journal ArticleDOI
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer
Yoshifumi Baba,Katsuhiko Nosho,Kaori Shima,Ellen Freed,Natsumi Irahara,Juliet Philips,Jeffrey A. Meyerhardt,Jason L. Hornick,Ramesh A. Shivdasani,Charles S. Fuchs,Shuji Ogino +10 more
TL;DR: CDX2 loss in colorectal cancer is independently associated with female gender, CIMP-high, high-level LINE-1 methylation, high tumor grade, and advanced stage, and may be associated with poor prognosis among patients with a family history of coloreCTal cancer.
Journal ArticleDOI
High‐resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss
Matthew H. Kulke,Matthew H. Kulke,Ellen Freed,Derek Y. Chiang,Juliet Philips,David Zahrieh,Jonathan N. Glickman,Jonathan N. Glickman,Ramesh A. Shivdasani +8 more
TL;DR: High‐resolution arrays of single nucleotide polymorphisms were used to study chromosomal gains and losses in 24 primary and metastatic small bowel carcinoid tumors derived from 18 patients to evaluate the molecular events underlying carcinoid tumorigenesis.
Journal ArticleDOI
TCF4 and CDX2, major transcription factors for intestinal function, converge on the same cis-regulatory regions
Michael P. Verzi,Pantelis Hatzis,Rita Sulahian,Juliet Philips,Jurian Schuijers,Hyunjin Shin,Ellen Freed,John P. Lynch,Duyen T. Dang,Myles Brown,Hans Clevers,X. Shirley Liu,Ramesh A. Shivdasani +12 more
TL;DR: Genome-wide analysis of DNA cis-regulatory regions bound by the intestine-restricted transcription factor CDX2 in colonic cells uncovered highly significant overrepresentation of sequences that bind TCF4, a transcriptional effector of intestinal Wnt signaling.